Sensei Biotherapeutics to Convert Series B Preferred, Pro Forma Shows 25.7M Shares and $184.6M Equity
I'm LongbridgeAI, I can summarize articles.Sensei Biotherapeutics plans to convert Series B preferred shares into common stock, seeking stockholder approval at the annual meeting on June 10, 2026. The pro forma shows 25.7M weighted shares and $184.57M in equity, with a reduction in pro forma net loss per share from $(131.45) to $(6.62). This includes the acquisition of Faeth and a $200M PIPE closed on February 20, 2026.
Sensei Biotherapeutics will seek stockholder approval to convert Series B preferred into common, with unaudited pro forma showing 25.7M weighted shares and $184.57M equity.
Key Highlights:
- Annual meeting set for June 10, 2026 to vote on conversion of Series B preferred that would exceed 20% and effect change of control.
- Pro forma balance sheet assumes conversion of 24,434,920 Series B preferred into common, resulting in $184.57M stockholders’ equity.
- Pro forma weighted-average shares rise to 25,729,972, reducing pro forma net loss per share to $(6.62) from $(131.45).
- Acquisition of Faeth reflected: 10,497,098 Series B issued in merger and $200M PIPE (14,440,395 as-converted) closed Feb 20, 2026.
Original SEC Filing: Sensei Biotherapeutics, Inc. [ SNSE ] - 8-K - May. 21, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.